Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA

JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA

March 18, 2025

a250318_00.png

a250318_01.png

Previous: SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Next: SYH2051 (SELECTIVE ATM INHIBITOR) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号

Wechat